

CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised

- *Leptospira interrogans*, serovar Canicola, strain 601903, Inactivated
- Canine parainfluenza virus, strain Manhattan, Live
- *Leptospira interrogans*, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Product identification

Medicine name:

CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS

Active substance:

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated

Canine parainfluenza virus, strain Manhattan, Live

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
4350.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Canine parainfluenza virus, strain Manhattan, Live
4.80 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
4250.00 enzyme-linked immunosorbent assay unit / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI08

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Package description:

Plastic box of 1 vial of lyophilisate and 1 vial of suspension

Cardbox of 100 vials of lyophilisate and 100 vials of suspension

Cardbox of 50 vials of lyophilisate and 50 vials of suspension

Cardbox of 25 vials of lyophilisate and 25 vials of suspension

Cardbox of 10 vials of lyophilisate and 10 vials of suspension

Cardbox of 1 vial of lyophilisate and 1 vial of suspension

Plastic box of 100 vials of lyophilisate and 100 vials of suspension

Plastic box of 50 vials of lyophilisate and 50 vials of suspension

Plastic box of 25 vials of lyophilisate and 25 vials of suspension

Plastic box of 10 vials of lyophilisate and 10 vials of suspension

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Virbac

Marketing authorisation date:

8/05/2017

Manufacturing sites for batch release:

Virbac

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 119034

Date of authorisation status change:

15/06/2022

Reference member state:

France

Procedure number:

FR/V/0311/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia
Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg
Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 3/11/2025

Updated on: 13/03/2026

[Download](#)

eu-puar-frv0311001-mr-rpe294-en.pdf